Kanyon's shopping mall was 98.95% occupied at the end of the first quarter of 2026. The office block is not an empty tower either; occupancy is 94.3%. In Levent, shop doors are open, the car park is turning, rent is being booked. But the harder sentence in the same file wipes the makeup off ECILC's face: the company itself has effectively no production activity; the structure is a holding company working through subsidiaries and associates.
That is why reading ECILC only as a "pharmaceutical company" means walking through Kanyon's doors and missing the back room of the balance sheet. The real weight inside the share is 38.25 billion TL of long-term financial investments and 23.77 billion TL of investment property. Total: 62.02 billion TL. Market capitalization on May 20, 2026: 56.98 billion TL. The book stands above the market.
But the income statement is not as comfortable. The health segment made 2.49 billion TL of external sales in the first quarter and posted a 353 million TL operating loss. The parent-company loss was 924 million TL. Operating cash flow was also negative 42 million TL. So the question is not as simple as "is it cheap below book value?" The better question is this: is the market over-punishing a valuable asset box, or is it right not to trust the earnings engine?
There are real stones inside this asset box. Half of Kanyon and the entire office block sit among investment properties; the financial report says Kanyon generated 224.2 million TL of rental income in three months. On the Ayazaga side, there is a revenue-sharing and construction-for-land contract with Artas; ECILC's project revenue share is 47%. After the zoning application, roughly 41.5 thousand square meters of title deed area was formed, but the project is still waiting at the approval and license threshold.
The largest item on the financial investment side is the Eczacibasi Holding stake. ECILC owns 37.28% of the Holding; this stake is carried under financial investments at 38.19 billion TL. But the report openly writes the sentence that should be whispered into the minority investor's ear: ECILC has no directing influence or control over Eczacibasi Holding's operating and investment policies. There is value; the button is on someone else's desk.
That is why treating book value as cash would be a mistake. Kanyon is physical and full, but Kanyon's valuation is Level 3; it is not an asset priced every minute on an active screen. The Eczacibasi Holding stake is large, but it is a financial asset with no quoted market price, carried through annual valuation techniques. The balance sheet is strong; but for a minority investor, the speed at which that balance sheet can turn into cash is limited.
The real fracture is on the health side. Gensenta, Eczacibasi Ilac Pazarlama and pharmaceutical trade are the engine carrying ECILC's "pharma" name. In the first quarter, the health segment produced 785 million TL of gross profit; then general administrative, marketing-sales and R&D expenses exceeded that gross profit. Other operating income gave it some air, but the operating result was still negative 353 million TL. The real estate development segment, in the same quarter, generated 255 million TL of sales and 228 million TL of operating profit.
| Item | 2026Q1 | Read-through |
|---|---|---|
| Health segment | TRY 2.49bn external revenue; TRY 353mn operating loss | Gross profit exists, but the expense base is still eating it. |
| Real estate development | TRY 255mn external revenue; TRY 228mn operating profit | Kanyon's rent machine is working. |
| Consolidated result | TRY 924mn parent loss; TRY 42mn operating cash outflow | The loss is not just an accounting display; cash has not convinced yet. |
Sekerpinar is not a dry sentence in this picture; it is the physical stage of the matter. All production activities at Gensenta's Sekerpinar active pharmaceutical ingredient production facility were permanently stopped as of March 31, 2026; the employment contracts of 44 personnel were terminated. Management cites changes in demand conditions, production efficiency and cost optimization as the reason. This may be a company cutting a loss-making muscle. But it also shows that the Gensenta acquisition is still being digested.
Another story is being built in Yenibosna. Gensenta's Vial 4 investment has a budget of roughly 32 million euros; the target is a 60% increase in sterile liquid vial capacity and a 24% increase in lyophilized vial capacity. The investment incentive certificate covers a fixed investment amount of 1.35 billion TL. Under YTAK, a total of 775 million TL of credit is planned; the first 546 million TL tranche is stated to have been disbursed in April 2026. So if the closed line is cost discipline, Vial 4 is the growth claim. Both can be true at the same time.
On the Eczacibasi Ilac Pazarlama side, the pressure is more political and more daily. Reimbursed drug prices are determined by the Ministry of Health's reference pricing system and the euro value used in pharmaceutical pricing. As of April 1, 2026, this value is 29.1164 TL. The gap between the current euro and the official pharma euro strains companies, especially importers. Except for freely priced food supplements, EIP lives inside this framework for most of the prescription and non-prescription products it sells.
That is why Dynavit matters. The food supplement brand opens up a freely priced area; a letter of intent was signed between EIP and BV Portfoy for the separation of Dynavit activities and the establishment of a venture capital fund that will invest in the new company. This is not cash yet from a valuation perspective. But if done well, it means placing the operational value ECILC has failed to explain to the market inside a separate glass case.
Valuation here must pass through two doors.
The first door is the book multiple. Equity attributable to the parent is 66.24 billion TL; market capitalization is 56.98 billion TL. The market pays 0.86x book. That alone does not allow a verdict of "cheap." In holding structures, control, liquidity, cash conversion and the family table demand a discount. But most of this book is not an empty promise; financial investments and investment properties almost equal the entire parent equity. The 0.86x multiple therefore deserves attention, but it cannot decide the case alone.
The second door is residual value sensitivity. If we take the asset block at book, the health segment's net assets at half multiple, and other net burdens as they are, the implied value becomes 61.3 billion TL; this is roughly 7.6% above market value. The health net asset figure here is half of the 9.89 billion TL net value between the health assets of 16.16 billion TL and health liabilities of 6.26 billion TL in the segment table; the other net burden is the remaining -5.67 billion TL residual item needed to reconcile with parent equity. Put a 10% discount on the same asset block and the value falls to 55.1 billion TL, slightly below the market. Put a 20% discount on it and the result is 48.9 billion TL. So today's price says this: the market is not imposing a brutally heavy punishment on ECILC; it is pricing in an asset discount of around 10% and limited confidence in the health side.
| Scenario | Asset block | Health net asset | Other net drag | Implied value | Gap to market value |
|---|---|---|---|---|---|
| Book flat, health at 0.5x | 62.02 | 4.95 | -5.67 | 61.29 | +7.6% |
| 10% asset discount | 55.81 | 4.95 | -5.67 | 55.09 | -3.3% |
| 20% asset discount | 49.61 | 4.95 | -5.67 | 48.89 | -14.2% |
This bridge also sets the verdict. Based on today's evidence, ECILC is fairly valued. To call it "cheap," one must see either cash flow or margin repair from the health engine. To call it "expensive," one must ignore Kanyon, Ayazaga, the Eczacibasi Holding stake and the low pressure from net financial debt. Neither is correct.
The fair anti-thesis is strong. If Gensenta's new capacity does not turn into profit, Vial 4 becomes only a more expensive bill for patience. If the official pharma euro keeps lagging the current exchange rate, EIP's gross profit will struggle against personnel and marketing expenses. If the Ayazaga license process drags on, the Dynavit separation does not produce a priceable transaction, and the Holding stake remains a silent OCI item, then a 20% asset discount is not cruel; it is reasonable.
The upside path is not fairy-tale either. If Kanyon's occupancy is preserved and rental income breathes against inflation, if licenses and project visibility arrive at Ayazaga, if external capital puts a real value on Dynavit, if the licenses acquired from Sanofi turn into local production through technology transfer by 2029, and if Vial 4 converts sterile capacity into gross margin, the market may have to apply a lower discount to this asset box than it does today. The first signal, however, will not be a romantic project announcement. It will be positive operating cash flow.
There are three data points to watch. First, the health segment's operating loss: is gross profit really beginning to carry expenses? Second, cash flow: is operating cash turning positive, or does the asset book continue to be the fuel of growth? Third, visible value: on Ayazaga, Dynavit, the Sanofi licenses and Vial 4, are the sentences moving from project toward cash?
ECILC is not for the investor looking for a fast catalyst. It also misleads the investor who wants pure pharmaceutical growth. This share is for the investor who can read an asset book, understands why a holding discount exists, and can patiently follow the burden of proof on the operation. To own it means taking Kanyon's occupancy while also carrying the quarter in which pharma remains in the red.